Clinical trial

Sequential Vaccinations in Prostate Cancer Patients

NCT00060528 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00060528
Title Sequential Vaccinations in Prostate Cancer Patients
Official title A Phase I/II Pilot Study of Sequential Vaccinations With rFowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM) Alone, or in Combination With rVaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), and the Role of GM-CSF, in Men With Prostate Cancer
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 1/Phase 2
Study type Interventional
Conditions Prostatic Neoplasms
Intervention type Drug
Interventions Recombinant Fowlpox-GM-CSF, Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM), Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM), Recombinant Human GM-CSF
Enrollment 32
Start date May 22, 2003
Primary completion Mar 7, 2006
Completion Jun 8, 2009
First posted May 7, 2003
Last update posted Oct 26, 2017
Countries United States

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies